Leniolisib phosphate

First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and older and a multinational pediatric study in children aged 4 to 11 years First approval of Joenja covering children aged 4 to 11 with APDS Leiden, the Netherlands, March 24, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome (APDS) in adult and pediatric patients aged 4 years and older. With this approval, Joenja becomes the first treatment approved in Japan specifically for APDS and the first approved treatment anywhere globally, for children aged 4 to 11 with the disease. Under an agreement with Pharming, OrphanPacific, Inc. serves as the Marketing Authorization Holder for Joenja in Japan and in collaboration with Pharming, is responsible for supply and distribution of the product. The launch of Joenja is expected following agreement with the MHLW on its National Health Insurance drug price. Professor Hirokazu Kanegane, MD, PhD, Department of Child Health and Development at the Graduate School of Medical and Dental Sciences, Institute of Science Tokyo commented: “Patients with APDS in Japan have until now relied largely on supportive care, so this approval marks an important step forward for the APDS community. This approval introduces the first approved targeted treatment option for this rare primary immunodeficiency in Japan, and has the potential to help reduce the burden of disease for patients and their families.” Leverne Marsh, Chief Commercial Officer of Pharming, commented: “The approval of Joenja for patients as young as 4 years of age is an important milestone for the APDS community in Japan. As the first treatment approved specifically for APDS in the country, it is the only targeted treatment option for patients and families affected by this rare and progressive disease. It also marks the first approval globally for children aged 4 to 11 with APDS. Together with OrphanPacific, we look forward to working through the next steps to help make Joenja available to patients in Japan as quickly as possible.” The MHLW based the approval on data from Pharming’s Phase III clinical program for leniolisib in APDS, including the global, randomized, placebo-controlled study in patients aged 12 years and older, in which leniolisib met its co-primary endpoints by significantly reducing lymphadenopathy and significantly increasing the percentage of naïve B cells out of total B cells. This reflects a clinically relevant impact on immune dysregulation and deficiency which are hallmarks of APDS. Leniolisib was generally well tolerated with the most common adverse reactions (>10%) being headache, sinusitis, and atopic dermatitis. Supporting Phase III evidence also included the open-label Japanese study in patients aged 12 years and older, as well as positive data from the open-label, multinational Phase III study in children aged 4 to 11 years, including sites in Japan, which showed improvements over 12 weeks in reduced lymphadenopathy and increased percentage of naïve B cells from total B cells. The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) evaluated the application under the Priority Review pathway following the Orphan Drug Designation granted by the MHLW in May 2023. Joenja® is approved and marketed in the United States and the United Kingdom for patients 12 years of age and older with APDS. About Activated Phosphoinositide 3-Kinase δ Syndrome (APDS) APDS is a rare primary immunodeficiency that was first characterized in 2013. APDS is caused by variants in either one of two identified genes known as PIK3CD or PIK3R1, which are vital to the development and function of immune cells in the body. Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway, which causes immune cells to fail to mature and function properly, leading to immunodeficiency and dysregulation 1 , 2 , 3 APDS is characterized by a variety of symptoms, including severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy. 4 , 5 Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, it has been reported that people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay. 6 As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma. 4 - 7 A definitive diagnosis can be made through genetic testing. APDS affects approximately 1 to 2 people per million worldwide. 8 About Joenja® (leniolisib) Leniolisib is an oral small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor approved as the first and only targeted treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in the U.S., U.K., Australia and Israel in adult and pediatric patients 12 years of age and older and in Japan for patients 4 years of age and older. Leniolisib inhibits the production of phosphatidylinositol-3-4-5-trisphosphate, which serves as an important cellular messenger and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism. Results from a randomized, placebo-controlled Phase III clinical trial demonstrated statistically significant improvement in the coprimary endpoints, reflecting a favorable impact on the immune dysregulation and deficiency seen in these patients, and open label extension data has supported the safety and tolerability of long-term leniolisib administration. 9 , 10 Leniolisib is currently under regulatory review for the treatment of APDS in the European Economic Area, Canada and several other countries. Leniolisib is also being evaluated in two Phase II clinical trials in primary immunodeficiencies (PIDs) with immune dysregulation. The safety and efficacy of leniolisib has not been established for PIDs with immune dysregulation beyond APDS. About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S. For more information, visit and find us on LinkedIn . Forward-looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. Inside Information This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. References Lucas CL, et al. Nat Immunol. 2014;15(1):88-97. Elkaim E, et al. J Allergy Clin Immunol. 2016;138(1):210-218. Nunes-Santos C, Uzel G, Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687. Coulter TI, et al. J Allergy Clin Immunol. 2017;139(2):597-606. Maccari ME, et al. Front Immunol. 2018;9:543. Jamee M, et al. Clin Rev Allergy Immunol. 2020 Dec;59(3):323-333. Condliffe AM, Chandra A. Front Immunol. 2018;9:338. Vanselow S, et al. Frontiers in Immunology. 2023;14:1208567. Rao VK, et al Blood. 2023 Mar 2;141(9):971-983. Rao VK, et al. J Allergy Clin Immunol 2024;153:265-74. For further public information, contact: Investor Relations Michael Levitan, VP Investor Relations & Corporate Communications T: +1 (908) 705 1696 E: investor@pharming.com Media Relations Global: Saskia Mehring, Corporate Communications Manager T: +31 6 28 32 60 41 E: media.relations@pharming.com U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming) T: +1 (917) 882-9038 Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming) T: +31 6 53 81 64 27 Attachment FINAL_Pharming Group announces approval of Joenja® in Japan_EN_24Mar2026

Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by 15% to US$106.5 million, compared to the fourth quarter 2024 RUCONEST® full year revenue increased by 26% to US$317.9 million and fourth quarter revenue increased by 9% to US$86.7 million Joenja® revenue increased by 29% to US$58.2 million and fourth quarter revenue increased by 53% to US$19.8 million Achieved US$25.8 million operating profit in 2025, compared to a loss in 2024 Achieved US$54.7 million net cash flow from operations in 2025, compared to negative cash flow in the prior year 2026 total revenue guidance of US$405.0 – US$425.0 million (8% to 13% growth), driven by significant and accelerating growth for Joenja® and continued growth for RUCONEST® Advancing the clinical pipeline with key 2026 milestones including Phase II leniolisib readouts in PIDs with immune dysregulation and pivotal FALCON study enrollment completion for napazimone (KL1333) in primary mitochondrial disease Pharming to host a conference call today at 13:30 CET (8:30 am EDT) Leiden, the Netherlands, March 12, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2025. Chief Executive Officer, Fabrice Chouraqui commented: “2025 was a defining year for Pharming and reflects the focus and discipline our teams have brought to executing our strategy. We outperformed revenue guidance and delivered strong financial performance, with total revenues up 27%, driven by continued RUCONEST® growth and rising demand for Joenja® (leniolisib). With its efficacy, reliability and rapid onset of action, RUCONEST® remains an established on-demand treatment option for difficult to treat patients. Joenja® performance accelerated in 2025, with growth driven by a 25% increase in patients on paid therapy in the U.S. We have identified approximately 1,000 APDS patients globally, reinforcing the expanding opportunity for Joenja® as diagnosis and patient identification continue to improve. We also demonstrated disciplined cost management, delivering US$25.8 million in operating profit and US$54.7 million in net cash flow from operations in 2025. This marks an important inflection point and strengthens our ability to fund growth and long-term investment. Building on this momentum, we plan to further enhance capital allocation to drive growth. We expect 2026 total revenues in the range of US$405 million to US$425 million, representing 8% to 13% growth, driven by both Joenja® and RUCONEST®. Our pipeline is a significant value driver, and we highlighted its depth and upcoming catalysts at our recent Investor Day. Entering 2026, our priorities are clear: reinforce RUCONEST® as a cornerstone on-demand therapy for difficult to treat HAE patients, accelerate Joenja®’s expansion, and advance our pipeline to broaden our impact in rare disease. We continue to expect Phase II read-outs for leniolisib in broader primary immunodeficiencies with immune dysregulation in the second half of 2026 and are on track to complete enrollment in the pivotal FALCON study of napazimone (KL1333) in 2026, with data readout anticipated in late 2027. This momentum reinforces the strength of our business and positions us to advance our high-value pipeline, delivering long-term value for shareholders and meaningful impact for rare disease patients.” Fourth quarter and full year 2025 highlights Commercialized products RUCONEST® marketed for the treatment of acute HAE attacks RUCONEST® growth continued in the fourth quarter of 2025, with revenue of US$86.7 million, a 9% increase compared to the fourth quarter of 2024. Revenue for the full year 2025 reached a record US$317.9 million, representing 26% year-over-year growth. In the U.S. market, we continued to expand our patient and prescriber base during the quarter and throughout the year. Revenue growth over the prior year reflects the benefit of a larger patient base, including patients with HAE with normal C1-INH. With its efficacy, reliability and rapid onset of action via IV administration, RUCONEST® remains an established on-demand treatment option for patients experiencing more severe or frequent attacks who have failed other on-demand medications. During the year, we increased the RUCONEST® physician prescriber base by 6%. Unit sales volume in the U.S. increased by 2% in the fourth quarter and 20% for the full year. Joenja® (leniolisib) marketed for the treatment of APDS Joenja® revenue increased to US$19.8 million in the fourth quarter of 2025, a 53% increase compared to the fourth quarter of 2024. Revenue for the full year 2025 increased to US$58.2 million, a 29% increase compared to 2024. Revenue growth in the fourth quarter of 2025 was driven by a significant increase in patients on paid therapy in the U.S. and increased demand in international markets, including strong patient uptake in the U.K. following the April 2025 launch and purchases under government-supported access programs. The U.S. market contributed 86% of 2025 revenues, while the EU and Rest of World contributed 14%. As of December 31, 2025, 120 patients were on paid therapy in the U.S., representing a 25% increase from the 96 patients at the end of 2024. The number of patients on paid therapy in the U.S. increased by 24 during 2025, compared to an increase of 16 in 2024. The number of U.S. patients diagnosed with APDS that we have identified increased by 40 in 2025 compared to an increase of 18 in 2024. APDS patient finding As of December 31, 2025, we have identified 998 diagnosed APDS patients of all ages globally, including 274 patients in the U.S. and 382 in core markets outside of the U.S. Of the identified patients in the U.S., 181 patients are 12 years of age or older and currently eligible for treatment with Joenja®, while 52 are between 4 and 11 years of age. VUS patient reclassification We previously announced that genetic testing laboratories were evaluating data from a study published in June 2025 in the journal Cell by researchers at Columbia University to determine the process and potential for reclassifying variants of uncertain significance, or VUS, enabling providers to genetically confirm APDS diagnoses. Based on this evaluation, additional complementary evidence will be required for variant interpretation by genetic testing laboratories. We are planning new experiments to generate the data needed for genetic testing laboratories to evaluate VUSs identified in patients who have undergone genetic testing for APDS or other immunodeficiencies. There are currently over 1,800 known U.S. patients with a VUS in the PIK3CD and PIK3R1 genes implicated in APDS. We expect to provide an estimate of how many of these patients may be diagnosed with APDS following completion of these experiments. Joenja® (leniolisib) development Leniolisib for APDS As of December 31, 2025, there are 175 APDS patients in either a leniolisib Expanded Access Program (compassionate use), an ongoing clinical study, or a paid access program. Pediatric label expansion On January 30, 2026, we received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding our supplemental New Drug Application (sNDA) for Joenja® (leniolisib) for the treatment of APDS in children aged 4 to 11 years. The FDA requested additional pediatric pharmacokinetic (PK) data and clarification related to an analytical batch testing method. We believe we can address the clinical pharmacology and batch testing methodology issues outlined in the letter, and have requested a Type A meeting with the FDA to discuss the Agency’s feedback and align on the path forward for resubmission. The meeting is expected to occur in March 2026. European Economic Area (EEA) We completed the required manufacturing activities and quality controls requested by the European Medicine Agency’s (EMA) Committee for Human Medicinal Products (CHMP) and submitted our comprehensive response, including supporting data, by the January 2026 deadline. We now expect a CHMP opinion on the Marketing Authorisation Application (MAA) for leniolisib in adult and pediatric patients aged 12 years and older with potential EC approval in the first half of 2026. Japan A decision by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) is expected by the end of March 2026 on our new drug application (NDA) for leniolisib for the treatment of APDS in adult and pediatric patients 4 years of age and older. Additional markets We submitted a response with additional CMC data to Health Canada at the end of January 2026. A decision on the regulatory submission in Canada for APDS patients 12 years of age and older is expected by mid-year. Leniolisib for additional primary immunodeficiencies (PIDs) Two Phase II clinical trials are evaluating leniolisib for additional primary immunodeficiencies (PIDs) with immune dysregulation, which represent substantially larger patient populations than APDS. These include (i) genetically identifiable PIDs with immune dysregulation linked to altered PI3Kδ signaling and (ii) common variable immunodeficiency, or CVID, with immune dysregulation identified independently of genetics. We outlined the scientific and clinical rationale supporting the expansion of leniolisib into these patient populations at an Investor Day held on February 3, 2026. Patient enrollment in both clinical trials is now complete and we anticipate trial read-outs in the second half of 2026. Napazimone (KL1333) for mitochondrial DNA-driven primary mitochondrial disease Napazimone (KL1333) is being evaluated in the pivotal FALCON clinical trial in adult patients with mtDNA-driven mitochondrial disease, and has the potential to become the first standard of care in this setting. Pharming management outlined the scientific and clinical rationale for the development of napazimone (KL1333) at the Investor Day held on February 3, 2026. Over 20 clinical sites in the trial are actively recruiting, and the number of sites is expected to expand during the first half of 2026. The program remains on track to complete enrollment this year, with trial readout anticipated in late 2027 and potential FDA approval by the end of 2028, if successful. Organizational updates On September 2, 2025, we announced that Mr. Kenneth Lynard was appointed as Chief Financial Officer, effective October 1, 2025. On November 6, 2025, we announced that Mrs. Leverne Marsh had been appointed as Chief Commercial Officer effective January 1, 2026, succeeding Mr. Stephen Toor. Financial Summary Consolidated Statement of Income Q4 2025 Q4 2024 2025 2024 Amounts in US$m except per share data Total Revenues 106.5 92.7 376.1 297.2 Cost of sales (21.1) (12.2) (45.5) (35.4) Gross profit 85.4 80.5 330.6 261.8 Other income 4.2 0.1 6.5 2.2 Research and development (32.1) (22.3) (100.4) (83.1) General and administrative (20.0) (24.7) (80.0) (70.7) Marketing and sales (31.3) (26.9) (131.0) (118.8) Other Operating Costs (83.4) (73.9) (311.3) (272.6) Operating profit (loss) 6.2 6.7 25.8 (8.6) Finance result (net) and share of result in associates (1.4) — (13.0) 0.1 Profit (loss) before tax 4.8 6.7 12.8 (8.5) Income tax credit (expense) 0.5 (3.8) (10.3) (3.3) Profit (loss) for the period 5.3 2.9 2.5 (11.8) Earnings per share Basic, attributable to equity holders of the parent (US$) 0.008 0.004 0.004 (0.018) Diluted, attributable to equity holders of the parent (US$) 0.007 0.004 0.004 (0.018) Segment information - Revenues Q4 2025 Q4 2024 2025 2024 Amounts in US$m Revenue - RUCONEST® (US) 84.3 78.2 311.7 246.6 Revenue - RUCONEST® (EU and RoW) 2.4 1.4 6.2 5.6 Total Revenues - RUCONEST® 86.7 79.7 317.9 252.2 Revenue - Joenja® (US) 15.4 11.8 50.1 40.5 Revenue - Joenja® (EU and RoW) 4.4 1.3 8.1 4.5 Total Revenues - Joenja® 19.8 13.0 58.2 45.0 Total Revenues - US 99.8 90.0 361.7 287.1 Total Revenues - EU and RoW 6.8 2.7 14.4 10.1 Total Revenues 106.5 92.7 376.1 297.2 Consolidated Balance Sheet December 31, 2025 December 31, 2024 Amounts in US$m Cash and cash equivalents, restricted cash and marketable securities 181.1 169.4 Current assets 299.5 278.4 Total assets 500.0 400.0 Current liabilities 115.8 73.8 Equity 277.1 221.1 Underlying figures are unrounded. Therefore, totals may differ slightly from the sum of individual items due to rounding effects in the presentation of this press release. Financial highlights Fourth quarter 2025 For the fourth quarter of 2025, total revenues increased by US$13.8 million, or 15%, to US$106.5 million, compared to US$92.7 million in the fourth quarter of 2024. RUCONEST® revenues amounted to US$86.7 million, a 9% increase compared to the fourth quarter of 2024. This increase in RUCONEST® revenues was primarily driven by volume growth and a price increase in the U.S. Joenja® revenues amounted to US$19.8 million in the fourth quarter of 2025, a 53% increase compared to the fourth quarter of 2024. This increase in Joenja® revenues was primarily driven by an increase in volume. Gross profit increased by US$4.9 million or 6% to US$85.4 million (4Q 2024: US$80.5 million), mainly due to the increase in revenues. This was partially offset by the first sales milestone payment for Joenja® of US$5.0 million included in cost of sales. Other income increased from US$0.1 million in the fourth quarter of 2024 to US$4.2 million in the fourth quarter of 2025, primarily driven by a US$3.9 million gain on the early termination of the DSP facility lease at Pivot Park in Oss, the Netherlands. The operating profit decreased 8% and amounted to US$6.2 million compared to US$6.7 million in the fourth quarter of 2024. Adjusted to exclude US$0.1 million of non-recurring Abliva acquisition-related expenses, US$4.1 million in one-off restructuring expenses, and the US$3.9 million gain on the early termination of the DSP facility lease, the operating profit amounted to US$6.5 million. The improved operating result was primarily driven by an increase in revenues, partially offset by higher operating expenses, which include a total of US$9.3 million in Abliva-related expenses, and the first sales milestone for Joenja® of US$5.0 million. The finance result (net) and share of result in associates amounted to a loss of US$1.4 million compared to US$— million in the fourth quarter of 2024. This was primarily driven by unfavorable EUR/USD exchange rate developments, resulting in a foreign currency loss of US$2.2 million compared to a gain of US$2.6 million in the fourth quarter of 2024, partially offset by higher results from fair value measurements of US$2.5 million and higher share of results in associates of US$1.4 million. In the fourth quarter of 2025, a net profit of US$5.3 million was realized, compared to a net profit of US$2.9 million in the fourth quarter of 2024. In addition to the aforementioned drivers, the net result was positively impacted by a tax credit of US$0.5 million compared to a tax expense of US$3.8 million in the fourth quarter of 2024. Cash generated from operations amounted to US$10.7 million, compared to US$9.3 million in the fourth quarter of 2024. Cash and cash equivalents, including restricted cash and marketable securities, increased from US$168.9 million at the end of third quarter of 2025 to US$181.1 million at the end of the fourth quarter of 2025. This increase was primarily driven by the net cash flows generated from operating activities. Full year 2025 In 2025, Pharming revenues increased by 27% to US$376.1 million. Operating profit improved from a US$8.6 million loss in 2024 to a US$25.8 million profit in 2025. Similarly, net profit improved from a US$11.8 million loss in 2024 to a US$2.5 million profit in 2025. This section will further elaborate on Pharming's financial performance in 2025. Revenues and Gross Profit Total revenues for 2025 grew by 27%, reaching US$376.1 million, compared to US$297.2 million in 2024. Total RUCONEST® revenues were 26% higher at US$317.9 million, compared to revenues of US$252.2 million for 2024. Joenja® revenues amounted to US$58.2 million in 2025, a 29% increase compared to revenues of US$45.0 million for 2024. This increase was primarily driven by a 37% increase in volume. Cost of sales increased by 29% from US$35.4 million in 2024 to US$45.5 million in 2025. Cost of inventories recognized as expenses in 2025 amounted to US$32.0 million compared to US$25.6 million in 2024, primarily due to the higher unit sales volume. The remainder of the increase in cost of sales in 2025 stems primarily from the higher royalty payments to Novartis on Joenja® sales of US$5.8 million (2024: US$4.9 million) and the first sales milestone payment for Joenja® of US$5.0 million (2024: US$— million), partially offset by lower impairment charges on inventory of US$2.7 million (2024: US$4.8 million). Gross profit increased by US$68.8 million, or 26%, to US$330.6 million for the year 2025. The primary driver for this increase was higher sales volumes of RUCONEST® and Joenja®. Other income Other income increased to US$6.5 million compared to US$2.2 million in 2024. Other income in 2025 was supported by the gain on the early termination of the DSP facility lease at Pivot Park in Oss, the Netherlands of US$3.9 million. Operating Profit (loss) and Other Operating Costs The operating profit amounted to US$25.8 million compared to an operating loss of US$8.6 million for the prior year. Adjusted to exclude US$10.3 million of non-recurring Abliva acquisition-related expenses (of which US$8.1 million is included in General and administrative expenses and US$2.2 million is included in Research and development expenses), US$4.1 million in one-off restructuring expenses, and the US$3.9 million gain on the early termination of the DSP facility lease, the operating profit amounted to US$36.4 million. The improved operating result was primarily driven by an increase in revenues, partially offset by higher operating expenses which include a total of US$29.7 million in Abliva-related expenses, and the first sales milestone for Joenja® of US$5.0 million. Excluding the Abliva-related expenses and restructuring expenses, other operating expenses increased by 2% compared to prior year. Finance result (net) and share of result in associates The finance result (net) and share of result in associates amounted to a loss of US$13.0 million compared to a gain of US$0.1 million in 2024. The year‑on‑year decline was primarily driven by foreign currency losses of US$7.2 million, compared to a gain of US$2.0 million in 2024, resulting from the strengthening of the euro against the US dollar. In addition, interest income declined as the Company reduced its investments in marketable securities during the year. These effects were partially offset by a higher share of results in associates of US$2.4 million. Income tax expense Income tax expense increased from US$3.3 million for the year ending December 31, 2024, to US$10.3 million for the year ending December 31, 2025. This tax expense mainly results from the profits of Pharming in the U.S. being taxed against a U.S. Federal and State combined tax rate of 27.96%, while the losses in the Netherlands only partly result in an offsetting tax credit, as the share-based compensation expenses and losses in associates are generally non-deductible based on Dutch tax law. Net result for the year The Company had a net profit of US$2.5 million in 2025, compared to a net loss of US$11.8 million in 2024. Intangible assets In 2025, intangible assets increased by US$74.5 million, from US$61.0 million in 2024 to US$135.5 million in 2025. The significant year‑on‑year growth is primarily attributable to the acquisition of Abliva AB, including the recognition of the intellectual property related to the napazimone (KL1333) program. The amortization relates to regular amortization of software, the RUCONEST® licenses (U.S. and EU) and the Joenja® license. The RUCONEST® license has a remaining amortization period of 12 years for the U.S. and 6 years for the EU. The Joenja® license has a remaining amortization period of 11 years. Property, plant and equipment The value of property, plant and equipment decreased from US$7.8 million in 2024 to US$7.2 million in 2025. This decline was primarily driven by regular depreciation (US$2.1 million) and positive foreign currency effects (US$0.8 million), partially offset by capital expenditures (US$0.7 million). Right-of-use assets The right-of-use assets increased from US$16.4 million in 2024 to US$16.7 million in 2025. This increase was primarily driven by remeasurements (US$2.4 million) and positive foreign currency effects (US$1.6 million), partially offset by regular depreciation (US$3.5 million) and the subsequent impairment of the remeasurement of the DSP facility at Pivot Park in Oss, the Netherlands (US$0.5 million). The 2025 building remeasurements were related to adjustments in the existing right-of-use assets to account for inflation-related higher lease payments. Investments Investments increased by US$4.4 million to US$8.6 million as of December 31, 2025. This increase was primarily driven by the capital contributions made to BioConnection of US$0.7 million, Pharming's share in the net result of BioConnection of US$0.6 million and a fair value increase of US$2.3 million in the preference share in BioConnection, carried at fair value through the statement of profit and loss (FVTPL). Inventories Inventories increased from US$55.7 million as of December 31, 2024, to US$64.9 million as of December 31, 2025 mainly as a result of foreign currency effects. Cash and cash equivalents and marketable securities Cash and cash equivalents alone increased by US$90.4 million to US$145.3 million as of December 31, 2025. Cash and cash equivalents is managed in combination with the marketable securities position. The combined total of cash and cash equivalents, together with restricted cash and marketable securities increased from US$169.4 million at year-end 2024 to US$181.1 million at year-end 2025. This increase was primarily driven by the positive operating cash flow of US$54.7 million as well as proceeds from exercise of share-based compensation awards during 2025, amounting to US$19.8 million in positive cashflows for 2025. This increase was primarily offset by purchases of Abliva shares totaling US$68.0 million. Shareholders' equity Shareholders' equity increased by US$56.0 million from US$221.1 million for the year ended December 31, 2024, to US$277.1 million for the year ended December 31, 2025. This increase was driven by transactions recognized directly in equity relating to share-based compensation and exercised options (totaling US$23.7 million) and the other comprehensive income of US$29.1 million. The other comprehensive income was primarily driven by currency translation differences. Convertible bond The convertible bond position has increased by US$15.7 million to US$98.1 million at year-end 2025, from US$82.4 million as of December 31, 2024. This increase was mainly driven by foreign currency effects of US$11.0 million resulting from the strengthening of the euro against the US dollar. Lease liabilities Lease liabilities decreased by US$12.2 million, moving from US$29.9 million as of December 31, 2024, to US$17.7 million as of December 31, 2025. This decrease was primarily driven by disposals of lease liabilities, amounting to US$13.7 million of which the main contributor was the early termination of the DSP facility lease at Pivot Park in Oss, the Netherlands. Trade and other payables Trade and other payables increased by US$39.3 million, moving from US$66.6 million as of December 2024, to US$105.9 million as of December 31, 2025. This increase was driven by the fee for the early termination of the DSP facility lease at Pivot Park in Oss, the Netherlands of US$12.3 million, the acquisition of Abliva AB resulting in an additional US$7.0 million in Trade and other Payables, as well as the first sales milestone for Joenja® of US$5.0 million. Outlook/Summary For 2026, the Company anticipates: Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected. Total operating expenses between US$330 million and US$335 million (6% to 8% growth), including US$60 million incremental R&D expenses to advance the pipeline and US$9 million structural G&A cost reductions based on the plan announced in October 2025. Continued RUCONEST® growth, and significant and accelerating Joenja® U.S. and x-U.S. growth. Progress towards additional regulatory approvals and commercial launches for leniolisib for APDS patients 12 years of age or older and for pediatric label expansion in key global markets. Top-line data readouts for the two ongoing leniolisib Phase II clinical trials in PIDs with immune dysregulation to expand the asset’s addressable patient population. Completion of enrollment in the pivotal FALCON clinical study for napazimone (KL1333) in mitochondrial DNA-driven primary mitochondrial diseases. Enhancing capital allocation to drive growth and build a leading rare disease company. Continued focus on potential acquisitions and in-licensing of clinical stage opportunities in rare diseases. Financing, if required, would come via a combination of our strong balance sheet and access to capital markets. No further specific financial guidance for 2026 is provided. Additional information Presentation The conference call presentation is available on the Pharming.com website from 07:30 CET today. Conference Call The conference call will begin at 13:30 CET/08:30 am EDT on Thursday, March 12. A transcript will be made available on the Pharming.com website in the days following the call. Please note, the Company will only take questions from dial-in attendees. Webcast Link: Conference call dial-in details: Additional information on how to register for the conference call/webcast can be found on the Pharming.com website. Financial Calendar 2026 Annual Report and 20-F 2025 April 2 1Q 2026 financial results May 7 Annual General Meeting of Shareholders May 28 2Q/1H 2026 financial results July 30 3Q 2026 financial results November 5 For further public information, contact: Investor Relations Michael Levitan, VP Investor Relations & Corporate Communications T: +1 (908) 705 1696 E: investor@pharming.com Media Relations Global: Saskia Mehring, Corporate Communications Manager T: +31 6 28 32 60 41 E: media.relations@pharming.com U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming) T: +1 (917) 882-9038 Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming) T: +31 6 53 81 64 27 About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S. For more information, visit and find us on LinkedIn . Risk profile We continue to closely monitor and manage the key risks and opportunities, and will respond appropriately to any emerging risk. We will issue a full overview of our risk pro our Annual report 2025 to be published on April 2, 2026. Related party transactions There are no material changes in the nature, scope, and (relative) scale in this reporting period compared to last year. Auditor’s involvement The Condensed Consolidated Interim Financial Statements have not been audited by the Company’s statutory auditor. Forward-looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. Inside Information This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Pharming Group N.V. Condensed Consolidated Financial Statements in U.S. Dollars (unaudited) For the period ended December 31, 2025 Condensed consolidated statement of income Condensed consolidated statement of comprehensive income Condensed consolidated balance sheet Condensed consolidated statement of changes in equity Condensed consolidated statement of cash flow CONDENSED CONSOLIDATED STATEMENT OF INCOME For the period ended December 31 Amounts in US$ ‘000 2025 2024 Revenues 376,134 297,200 Costs of sales (45,500) (35,399) Gross profit 330,634 261,801 Other income 6,528 2,177 Research and development (100,367) (83,147) General and administrative (79,958) (70,650) Marketing and sales (130,995) (118,802) Other Operating Costs (311,320) (272,599) Operating profit (loss) 25,842 (8,621) Fair value gain (loss) on revaluation 2,345 4,990 Other finance income 2,176 6,843 Other finance expenses (18,140) (9,944) Finance result (net) (13,618) 1,889 Share of net profits (loss) in associates using the equity method 623 (1,760) Profit (loss) before tax 12,847 (8,492) Income tax credit (expense) (10,310) (3,349) Profit (loss) for the period 2,538 (11,841) Attributable to: Equity holders of the parent 2,851 (11,841) Non-controlling interests (313) — Earnings per share Basic earnings per share (US$) 0.004 (0.018) Diluted earnings per share (US$) 0.004 (0.018) CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME For the period ended December 31 Amounts in US$ ‘000 2025 2024 Profit (loss) for the period 2,538 (11,841) Currency translation differences 29,060 (11,980) Items that may be subsequently reclassified to profit or loss 29,060 (11,980) Fair value remeasurement investments — 79 Items that shall not be subsequently reclassified to profit or loss — 79 Other comprehensive income (loss), net of tax 29,060 (11,901) Total comprehensive income (loss) for the period 31,598 (23,742) Attributable to: Equity holders of the parent 31,828 (23,742) Non-controlling interests (230) — CONDENSED CONSOLIDATED BALANCE SHEET Amounts in US$ ‘000 December 31, 2025 December 31, 2024 Non-current assets Intangible assets 135,538 61,039 Property, plant and equipment 7,233 7,752 Right-of-use assets 16,738 16,382 Long-term prepayments 94 90 Deferred tax assets 31,017 30,544 Investment accounted for using the equity method 1,944 466 Investment in debt instruments designated as at FVTPL 6,703 3,767 Restricted cash 1,227 1,505 Total non-current assets 200,495 121,545 Current assets Inventories 64,902 55,724 Trade and other receivables 54,704 54,823 Restricted cash 761 — Marketable securities 33,796 112,949 Cash and cash equivalents 145,305 54,944 Total current assets 299,469 278,440 Total assets 499,963 399,985 Equity Share capital 8,009 7,769 Share premium 513,257 488,990 Other reserves 28,819 (209) Accumulated deficit (272,983) (275,489) Total equity 277,102 221,061 Non-current liabilities Convertible bonds 92,719 78,154 Lease liabilities 14,351 26,968 Total non-current liabilities 107,070 105,122 Current liabilities Convertible bonds 5,336 4,245 Provisions 1,187 — Trade and other payables 105,899 66,611 Lease liabilities 3,369 2,946 Total current liabilities 115,791 73,802 Total equity and liabilities 499,963 399,985 CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY For the period ended December 31 Attributable to owners of the parent Amounts in US$ ‘000 Share capital Share premium Other reserves Accumulated deficit Non-controlling interest Total equity January 1, 2024 7,669 478,431 (2,057) (265,262) — 218,781 Profit (loss) for the year — — — (11,841) — (11,841) Movement in reserves — — 1,555 (1,555) — — Other comprehensive income — — (11,901) — — (11,901) Total comprehensive income (loss) for the year — — (10,346) (13,395) — (23,742) Income tax expense from excess tax deductions related to share-based payments — — — (66) — (66) Movement in reserves — — (31) 31 — — Share-based compensation — — — 11,248 — 11,248 Options exercised / LTIP shares issued 100 10,559 — (8,044) — 2,615 Value of conversion rights of convertible bonds, net of tax — — 12,225 — — 12,225 Total transactions with owners, recognized directly in equity 100 10,559 12,194 3,169 — 26,022 Balance at December 31, 2024 7,769 488,990 (209) (275,489) — 221,061 January 1, 2025 7,769 488,990 (209) (275,489) — 221,061 Profit (loss) for the year — — — 2,851 (313) 2,538 Movement in reserves — — — — — — Other comprehensive income — — 28,977 — 83 29,060 Total comprehensive income (loss) for the year — — 28,977 2,851 (230) 31,598 Income tax expense from excess tax deductions related to share-based payments — — — 1,343 — 1,343 Movement in reserves — — (32) 32 — — Share-based compensation — — — 13,766 — 13,766 Options exercised / LTIP shares issued 241 24,266 — (14,581) — 9,926 Acquisition of a subsidiary — — — — 7,285 7,285 Capital contributions to a subsidiary with non-controlling interests — — — (706) 706 — Acquisition of non-controlling interests — — 83 (198) (7,761) (7,876) Total transactions with owners, recognized directly in equity 241 24,266 51 (345) 230 24,443 Balance at December 31, 2025 8,009 513,257 28,819 (272,983) — 277,102 CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS For the period ended December 31 Amounts in US$ ’000 2025 2024 Profit (loss) before tax 12,847 (8,492) Adjustments to reconcile net profit (loss) to net cash used in operating activities: Depreciation, amortization, impairment of non-current assets 11,216 16,070 Equity settled share based payments 13,766 11,248 Fair value loss (gain) on revaluation (2,345) (4,990) Loss (gain) on disposal of leases (3,733) 22 Other finance income (2,176) (6,843) Other finance expenses 17,901 9,887 Share of net losses (gains) in associates using the equity method (623) 1,758 Operating cash flows before changes in working capital 46,853 18,660 Changes in working capital: Inventories (1,288) (503) Trade and other receivables (3,355) (6,783) Payables and other current liabilities 17,820 (2,769) Provisions 1,187 — Restricted cash (285) (17) Total changes in working capital 14,079 (10,072) Interest received 2,069 5,201 Income taxes received (paid) (8,293) (15,584) Net cash flows generated from (used in) operating activities 54,708 (1,795) Capital expenditure for property, plant and equipment (749) (790) Investment intangible assets (6) (6) Disposal of investment designated as at FVOCI 224 2,098 Investment in associates using the equity method (739) — Purchases of marketable securities (2) (284,314) Proceeds from sale of marketable securities 85,001 314,630 Acquisition of a subsidiary, net of cash acquired (57,476) — Net cash flows generated from (used in) investing activities 26,252 31,618 Payment of lease liabilities (4,245) (4,008) Interests on lease liabilities (1,130) (1,141) Net proceeds of issued convertible bonds — 104,539 Repurchase of convertible bonds — (134,924) Interests on convertible bonds (5,067) (4,457) Acquisition of non-controlling interests (7,876) — Exercise of share-based compensation awards 19,813 5,579 Net cash flows generated from (used in) financing activities 1,495 (34,412) Increase (decrease) of cash 82,454 (4,589) Exchange rate effects 7,907 (2,208) Cash and cash equivalents at January 1 54,944 61,741 Total cash and cash equivalents at December 31 145,305 54,944 ---ENDS--- Attachment Pharming Group reports 4Q25_FY25 results_EN_12MAR26